NCT05323110View on ClinicalTrials.gov

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
Chronic Inflammatory Disease
Interventions
DRUG

CBS001

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

DRUG

Placebo

CBS001 matched placebo

Trial Locations (1)

NW10 7EW

HMR, London

Sponsors
All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

Capella Bioscience Ltd

INDUSTRY

NCT05323110 - Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers | Biotech Hunter | Biotech Hunter